Navigation Links
LCA-Vision Reports Second Quarter Financial Results

CINCINNATI, July 28 /PRNewswire-FirstCall/ -- LCA-Vision Inc. (Nasdaq: LCAV), a leading provider of laser vision correction services under the LasikPlus((R)) brand, today announced financial and operating results for the three and six months ended June 30, 2009.

Second Quarter 2009 Operational and Financial Results (all comparisons are versus the second quarter of 2008)

  • Revenue was $31.7 million compared with $54.2 million; adjusted revenue was $29.4 million compared with $49.2 million.
  • Procedure volume was 17,864 compared with 30,086.
  • Same-store revenue (73 vision centers) decreased 41.5%; adjusted same-store revenue decreased 39.7%.
  • Operating loss was $11.8 million compared with operating loss of $3.0 million; adjusted operating loss was $13.9 million compared with adjusted operating loss of $7.4 million. Operating loss and adjusted operating loss in the second quarter of 2009 included $1.6 million in restructuring and impairment charges.
  • Net loss was $6.9 million or $0.37 per share, compared with net loss of $573,000 or $0.03 per share.
  • Net cash provided by operating activities was $5.2 million. Compared with use of $3.1 million.
  • Cash and investments totaled $67.1 million as of June 30, 2009, an increase of $2.7 million from March 31, 2009 and up $7.6 million from December 31, 2008.

Year-to-date 2009 Operational and Financial Highlights (all comparisons are versus the first six months of 2008)

  • Revenue was $79.6 million compared with $133.8 million; adjusted revenue was $74.2 million compared with $123.2 million.
  • Procedure volume was 45,723 compared with 74,245.
  • Operating loss was $16.0 million compared with operating income of $7.5 million; adjusted operating loss was $20.8 million compared with adjusted operating loss of $2.0 million. Operating loss and adjusted operating loss included $2.5 million in restructuring and impairment charges and $0.8 million in consent revocation charges in 2009; operating income and adjusted operating loss in the first six months of 2008 included restructuring charges of $0.5 million.
  • Net loss was $9.7 million or $0.52 per share, compared with net income of $6.3 million or $0.34 per diluted share.

Since the first quarter of 2007, LCA-Vision has provided both adjusted revenue and operating income (loss) as a means of measuring performance that adjusts for the non-cash impact of accounting for separately priced extended warranties. A reconciliation of revenue and operating income (loss) as reported in accordance with U.S. Generally Accepted Accounting Principles (GAAP) is provided at the end of this news release. Management believes the adjusted information is more reflective of operating performance and, therefore, more meaningful to investors.

"As unemployment rates continue to rise and consumer confidence levels remain low, independent surveys and our own research indicate reluctance on the part of Americans to spend on elective, self-pay surgical procedures, resulting in further volume declines at our LasikPlus((R)) vision centers and throughout our industry. We anticipate continued volume softness throughout the remainder of 2009; however, as the economic downturn in 2008 had a greater impact on the second half of that year, we expect an improvement in year-over-year volume declines in the coming quarters," said Steven C. Straus, Chief Executive Officer of LCA-Vision. "We have been able to increase our average per-procedure price, excluding deferred revenue, by $87 over the past two quarters, following testing late last year that indicated some inelasticity of pricing.

"We are actively adapting to the current economic reality by becoming more nimble and flexible in our operations and have established company-wide business priorities in an effort to improve procedure volume, reduce costs and conserve cash," Straus added. "For example, we are implementing strategies to increase patient acquisition through partnering programs such as our new marketing relationship with one of the world's largest airlines, which will announce our partnership next week, joining the International Health, Racquet & Sportsclub Association, or IHRSA, as an associate member with its 9,750 member facilities, and by capitalizing on our relationships with health and vision plans that reduce the out-of-pocket cost to the patient - a leading factor in the decision-making process. We also are addressing patient candidacy through our internally developed second-opinion screening tools approved by our Medical Advisory Board, and are energizing our LCA-Vision/LasikPlus(R) staff to become more results-oriented through training and increasing accountability.

"Given the current economic environment, we plan to reduce marketing spending in the third quarter to approximately $6 million. Among our specific programs, we intend to use our segmentation research and integrated media programs in 14 top-producing LasikPlus((R)) markets. We also are working to upgrade our LasikPlus((R)) website through improved navigation and better integration with local center websites to allow for easier appointment scheduling and other patient-friendly capabilities. In addition to Internet and more traditional advertising, we will be expanding into various forms of social media in test markets in the third quarter, which include endorsements and ambassadors that will help to better establish our LasikPlus((R)) brand," he added.

LCA-Vision's Chief Financial Officer Michael Celebrezze commented, "We have taken multiple recent actions to improve cash flow and better align our expenses with procedure volume." Those actions include:

  • Reducing the size of the workforce by 9% in June. Headcount reductions since January 2008 have totaled 41%, generating a savings of approximately $17 million annually. We are also focused on moving toward an increasingly part-time workforce to further reduce compensation expenses.
  • Extending the freeze on wages, placing new center openings on hold and minimizing existing vision center renovations.
  • Closing three additional vision centers and one pre-operative center at the end of the second quarter based on underperformance. We may decide to re-enter some of these markets when economic conditions improve.
  • Reducing the number of excimer laser platform technologies from three to two in all LasikPlus(R) vision centers. Our revised relationships with Abbott Medical Optics and Alcon Inc. permitted us to reduce operating expenses, retire a portion of our capital lease obligations and add cash to our balance sheet.
  • Reduced capital expenditures to a minimum with only $178,000 spent year-to-date.

"Our financial results for the second quarter include $1.6 million in restructuring and impairment charges, yet we benefited from a $6 million tax refund related to the utilization of net operating losses generated in 2008. We generated $5.2 million in cash from operations during the quarter," Celebrezze added.

Advanced Vision Analysis

"We are ready to begin testing of our Advanced Vision Analysis (AVA) program, the first initiative in our Lifetime Vision model," said Straus. "We have integrated the advanced diagnostic equipment into our systems in the first of 13 test markets and expect to perform our initial procedure within the next few weeks. AVA constitutes a comprehensive eye analysis using new diagnostic tools to determine a patient's candidacy for laser vision correction and other refractive surgical procedures, as well as to screen for various eye diseases and irregularities. During the test, we intend to charge an AVA fee that will be credited toward the purchase of laser vision correction at our LasikPlus((R)) vision centers. AVA will allow us to more fully utilize our skilled surgeons, optometrists and staff with minimal capital expenditure. We intend to market this program through our website, in-center merchandising and by phone and email out-reach to former LasikPlus(R) patients in our test markets."

Near-Term Financial Outlook

LCA-Vision affirmed its intent to continue to manage cash and investments conservatively in 2009.

  • The company does not plan to open any new vision centers in 2009. LCA-Vision plans to restart its de novo new center opening program following improvements in the economy.
  • The company will continue to manage general and administrative expenses aggressively, which it now expects will decrease approximately 10% in 2009 compared with 2008.
  • The company expects marketing efficiency improvements in the third quarter with the lower spending levels.
  • The company expects center direct costs per center to decline in excess of 10% in 2009 compared with 2008.
  • The company expects capital expenditures to be approximately $1.0 million in 2009, down significantly from $14.9 million in 2008.

Comparing 2009 (the first full year of benefit from cost reductions) with 2007 (prior to cost reductions), the company expects monthly breakeven eyes per vision center to decline to 105 in 2009 from 125 in 2007, and expects the number of procedures per year required company-wide for breakeven cash flow from operations to decline to approximately 110,000 from 170,000. With the recent cost reductions, the company projects it has sufficient cash and investments to last beyond 2011 at 80,000 procedures annually.

Conference Call and Webcast

As previously announced, a conference call and webcast will be held today beginning at 10:00 a.m. Eastern time. To access the conference call, dial 866-322-1352 (United States and Canada) or 706-643-6246 (international callers). The webcast will be available at the investor relations section of LCA-Vision's website. A replay of the call and webcast will begin approximately two hours after the live call has ended. To access the replay, dial 800-642-1687 (United States and Canada) or 706-645-9291 (international callers) and enter the conference ID number: 174 595 66.

Forward-Looking Statements

This news release contains forward-looking statements based on current expectations, forecasts and assumptions of LCA-Vision that are subject to risks and uncertainties. The forward-looking statements in this release are based on information available to us as of the date hereof. Actual results could differ materially from those stated or implied in our forward-looking statements due to risks and uncertainties associated with our business. In addition to the risk factors discussed in our Form 10-K, there are a number of other risks and uncertainties associated with our business, including, without limitation, the successful execution of marketing strategies cost effectively to drive patients to our vision centers; the impact of low consumer confidence, competition in the laser vision correction industry; our ability to attract new patients; the possibility of long-term side effects and adverse publicity regarding laser vision correction; our ability to operate profitable vision centers and retain qualified personnel during periods of lower procedure volumes; the continued availability of non-recourse third-party financing for our patients on terms similar to what we have paid historically; and the future value of revenues financed by us and our ability to collect on such financings which will depend on a number of factors, including the worsening consumer credit environment and our ability to manage credit risk related to consumer debt, bankruptcies and other credit trends.

Further, the FDA's advisory board on ophthalmic devices is currently reviewing concerns about post-Lasik quality of life matters and the advisory board may propose a major new study on Lasik outcomes. The FDA or another agency could take legal or regulatory action against us or others in the laser vision correction industry. The outcome of this review or legal or regulatory action could potentially impact negatively the acceptance of Lasik. In addition, the acceptance rate of new technologies such as IntraLase((R)) or Wavelight((R)) technologies, and our ability to implement successfully new technologies on a national basis, creates additional risk. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we assume no obligation to update the information included in this news release, whether as a result of new information, future events or circumstances, or otherwise.

About LCA-Vision Inc./LasikPlus((R))

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus((R)) brand, operates 71 LasikPlus((R)) fixed-site laser vision correction centers in 31 states and 53 markets in the United States and a joint venture in Canada. Additional company information is available at and

                      Earning Trust Every Moment.

                                   Transforming Lives Every Day.

                                    LCA-Vision Inc.
                 Condensed Consolidated Statements of Operations
                  (Dollars in thousands except per share data)

                                     Three Months Ended    Six Months Ended
                                          June 30,             June 30,
                                       2009      2008      2009      2008

    Revenues - Laser refractive
     surgery                         $31,681   $54,181   $79,602  $133,750

    Operating costs and expenses
       Medical professional and
        license fees                   6,987    11,260    17,762    26,022
       Direct costs of services       17,269    20,045    35,085    44,496
       General and administrative      4,452     5,671     8,869    10,862
       Marketing and advertising       9,485    15,466    22,511    35,449
       Depreciation                    3,768     4,612     8,127     8,867
       Consent revocation charges         -          -       804         -
       Restructuring and impairment
        charges                        1,554        77     2,455       533

    Operating (loss) income          (11,834)   (2,950)  (16,011)    7,521

    Equity in earnings from
     unconsolidated businesses            48       265        75       321
    Net investment income                633       831       455     1,566
    Other income, net                     20         -        22        18

    (Loss) income before income
     taxes                           (11,133)   (1,854)  (15,459)    9,426

    Income tax (benefit) expense      (4,246)   (1,281)   (5,728)    3,123

    Net (loss) income                $(6,887)    $(573)  $(9,731)   $6,303

    (Loss) earnings per common share
       Basic                          $(0.37)  $ (0.03)   $(0.52)    $0.34
       Diluted                        $(0.37)  $ (0.03)   $(0.52)    $0.34

    Dividends declared per share         $ -    $ 0.06        $-     $0.24

    Weighted average shares
       Basic                          18,590    18,525    18,576    18,510
       Diluted                        18,590    18,525    18,576    18,570

                                      LCA-Vision Inc.
                        Condensed Consolidated Balance Sheets
                                 (Dollars in thousands)

                       Assets          June 30, 2009   December 31, 2008
    Current assets
       Cash and cash equivalents         $ 31,267          $  23,648
       Short-term investments              32,744             32,687
       Patient receivables, net of
        allowance for doubtful accounts of
        $1,397 and $1,465                   7,295              9,678
       Other accounts receivable            2,102              2,515
       Prepaid professional fees              705                911
       Prepaid income taxes                 5,863              8,957
       Deferred tax assets                  3,177              4,708
       Deferred compensation plan assets    2,427                  -
       Prepaid expenses and other           5,475              5,299

    Total current assets                   91,055             88,403

    Property and equipment                 92,990            121,734
    Accumulated depreciation and
     amortization                         (55,851)           (70,235)
    Property and equipment, net            37,139             51,499

    Long-term investments                   3,108              3,126
    Accounts receivables, net of allowance
     for doubtful accounts of $1,107 and
     $1,662                                 1,677              2,645
    Deferred compensation plan assets           -              2,196
    Deferred tax assets                     8,516              7,027
    Other assets                            5,715              2,586

    Total assets                        $ 147,210          $ 157,482

           Liabilities and Stockholders'
    Current liabilities
       Accounts payable                  $  8,315           $  8,169
       Accrued liabilities and other       11,872              8,608
       Deferred revenue                     7,049              9,107
       Deferred compensation liability      2,427                  -
       Debt and capital lease obligations
        maturing in one year                4,267              6,985
    Total current liabilities              33,930             32,869

    Long-term rent obligations              1,972              1,820
    Long-term debt  and capital lease
     obligations (less current portion)    11,601             14,120
    Deferred compensation liability             -              2,196
    Insurance reserve                       9,914              9,489
    Deferred license fee                    5,109                  -
    Deferred revenue                       10,708             14,003

    Stockholders' investment
       Common stock ($0.001 par value;
        25,229,336 and 25,199,734 shares
        and 18,603,824 and 18,552,985
        shares issued and outstanding,
        respectively)                          25                 25
       Contributed capital                174,281            174,206
       Common stock in treasury, at cost
        (6,625,512 shares and 6,646,749
        shares)                          (114,668)          (114,632)
       Retained earnings                   13,784             23,515
       Accumulated other comprehensive
        income (loss)                         554               (129)

    Total stockholders' investment         73,976             82,985

    Total liabilities and stockholders'
     investment                         $ 147,210          $ 157,482

                                    LCA-Vision Inc.
                   Condensed Consolidated Statements of Cash Flows
                                (Dollars in thousands)

                                                  Six Months Ended June 30,
                                                    2009            2008

    Cash flow from operating activities
    Net (loss) income                            $ (9,731)         $6,303
    Adjustments to reconcile net income to net
     cash provided by operating activities:
       Depreciation                                 8,127           8,867
       Provision for loss on doubtful accounts      1,957           3,325
       Loss on investments                            365               -
       Non cash restructuring charges               1,877               -
       Deferred income taxes                         (265)          1,686
       Stock based compensation                       568             612
       Insurance reserve                              425           1,070
       Equity in earnings of unconsolidated
        affiliates                                    (75)           (321)
       Changes in operating assets and liabilities
              Patient receivables                   1,394          (3,492)
              Other accounts receivable               413             999
              Prepaid income taxes                  3,094           4,736
              Prepaid expenses and other              880              80
              Accounts payable                        146          (6,821)
              Deferred revenue, net of
               professional fees                   (4,818)         (9,491)
             Accrued liabilities and other          8,165          (1,796)

    Net cash provided by operations               $12,522          $5,757

    Cash flow from investing activities
       Purchases of property and equipment           (178)        (12,590)
       Purchases of investment securities        (153,617)       (171,849)
       Proceeds from sale of investment
        securities                                153,900         170,910
       Other, net                                     263             787

    Net cash provided by (used in) investing
     activities                                   $   368        $(12,742)

    Cash flow from financing activities
       Principal payments of debt and capital
        lease obligations and loan                 (5,237)         (2,367)
       Proceeds from debt                               -          19,184
       Shares repurchased for treasury stock          (36)           (205)
       Exercise of stock options                        2             147
       Dividends paid to stockholders                   -          (4,447)

    Net cash (used in) provided by financing
     activities                                    (5,271)         12,312

    Increase in cash and cash equivalents           7,619           5,327

    Cash and cash equivalents at beginning of
     period                                        23,648          17,614

    Cash and cash equivalents at end of period    $31,267         $22,941   




(dollars in thousands)

To supplement its condensed consolidated financial statements presented in accordance with accounting principles generally accepted in the United States, LCA-Vision discusses adjusted revenues and operating income. Management utilizes this information as a means of measuring performance that adjusts for the non-cash impact of the accounting for separately priced extended warranties and believes that including this additional disclosure is meaningful to investors for the same reason.

Accordingly, this news release contains non-GAAP financial measures within the meaning of Regulation G promulgated by the Securities and Exchange Commission. A reconciliation of the difference between the non-GAAP measures with the most directly comparable financial measures calculated in accordance with GAAP follows:

                                 Three Months Ended         Six Months Ended
                                      June 30,                 June 30,
                                 2009         2008          2009        2008

         Reported             $ 31,681     $ 54,181       $79,602    $133,750
            Amortization of
             prior deferred
             revenue            (2,294)      (4,947)       (5,353)    (10,546)
         Adjusted revenue     $ 29,387     $ 49,234       $74,249    $123,204

    Operating (Loss) Income

         Reported             $(11,834)     $(2,950)     $(16,011)    $ 7,521
            Amortization of
             prior deferred
             revenue            (2,294)      (4,947)       (5,353)    (10,546)
            Amortization of
             prior professional
             fees                  229          494           535       1,054
         Adjusted operating
          (loss) income       $(13,899)    $ (7,403)     $(20,829)    $(1,971)

    For Additional Information

    Company Contact:                  Investor Relations Contact:
    Barb Kise                         Jody Cain
    LCA-Vision Inc.                   Lippert/Heilshorn & Associates
    513-792-9292                      310-691-7100

SOURCE LCA-Vision Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
2. LCA-Vision Announces Upcoming Investment Community Events
3. LCA-Vision Reports Fourth Quarter and Full-Year 2007 Financial Results
4. LCA-Vision Announces Quarterly Dividend Payment
5. LCA-Vision Announces the Opening of its 74th LasikPlus Vision Center in Des Moines, Iowa
6. LCA-Vision Announces the Opening of its 75th LasikPlus(R) Vision Center in Tulsa, Oklahoma
7. LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey
8. LCA-Vision to Present at the Bank of America 2008 Health Care Conference
9. LCA-Vision Conducts 2008 Annual Stockholder Meeting
10. LCA-Vision Announces Upcoming Investment Community Events
11. LCA-Vision Announces CFO Change
Post Your Comments:
(Date:11/27/2015)... ... 27, 2015 , ... The rapid speed at which Americans ... more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming ... The forgotten part of this equation: 80 percent of medical care occurs in ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is ... Pro X. With ProSidebar: Fasion, video editors can easily add an informative sidebar ... minimalist title opener. Utilize presets featuring self-animating drop zones, lines, bars, and text ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced today that ... (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics SL ERP ... partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment ...
(Date:11/27/2015)... ... 27, 2015 , ... Keeping in mind challenges faced by ... wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for ... parents and bring advice from parenting experts within their reach. As a part ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)... 25, 2015  Henry Schein, Inc., the world,s largest ... dental, medical and animal health practitioners, will unveil at ... Henry Schein ConnectDental® Pavilion , which brings together for ... solutions designed to help any practice or laboratory enter ... for a schedule of experts appearing at the Pavilion. ...
(Date:11/25/2015)... plc (NYSE: AGN ) today announced that it has ... Attorney General,s Office to end the litigation under ... the Attorney General over the decision of Forest Laboratories, Inc., ... now generic version of memantine immediate release tablets.  Under the ... counterclaims against New York , and has ...
Breaking Medicine Technology: